Concepedia

Publication | Open Access

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease

DOIFull Paper Access

119

Citations

28

References

2020

Year

Raymond Scott Turner, Michaeline Hebron, Abigail Lawler, Elizabeth Mundel, Nadia Yusuf, J. Nathan Starr, Muhammad Burhan Anjum, Fernando Pagán, Yasar Torres‐Yaghi, Wangke Shi,
Annals of Neurology

Abstract

Nilotinib is safe and achieves pharmacologically relevant cerebrospinal fluid concentrations. Biomarkers of disease were altered in response to nilotinib treatment. These data support a larger, longer, multicenter study to determine the safety and efficacy of nilotinib in Alzheimer's disease. ANN NEUROL 2020 ANN NEUROL 2020;88:183-194.

References

YearCitations

Page 1